Cheng G C, Briggs W H, Gerson D S, Libby P, Grodzinsky A J, Gray M L, Lee R T
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston Mass 02115, USA.
Circ Res. 1997 Jan;80(1):28-36. doi: 10.1161/01.res.80.1.28.
Although fibroblast growth factor-2 (FGF-2) participates in the response to vascular injury, the role of cellular deformation in FGF-2 release is incompletely understood. To test the hypothesis that mechanical strain tightly controls FGF-2 release, a novel device was used to impose homogeneous and uniform biaxial strain to human vascular smooth muscle cells. Release of FGF-2 increased with the number of cycles of strain (14%, 1 Hz); 1, 9, and 90 cycles of strain, respectively, released 0.55 +/- 0.06%, 2.9 +/- 0.3%, and 5.5 +/- 1.3% of the total cellular FGF-2 (versus 0.00 +/- 0.40% for control, P < .05), but release was not further increased for strain of 90 to 90,000 cycles. Mechanical release of FGF-2 depended on both the frequency and amplitude of deformation. For example, strain (90 cycles, 1 Hz) at 4% amplitude released only 0.1 +/- 0.1% of the total FGF-2, but strain at 14% and 33% amplitudes, respectively, released 5.7 +/- 0.5% and 19.0 +/- 3.0% of the FGF-2 cellular pool (P < .05), suggesting a strain amplitude threshold for FGF-2 release. Injury to a subpopulation of cells increased with the frequency and amplitude of strain, but cells were not injured by strains below 10% amplitude. Strain following pretreatment with heparin released 12.6 +/- 1.6% of the total FGF-2 (versus 15.8 +/- 0.9% for strain alone, P < .05), indicating that most FGF-2 was liberated from the nuclear or cytoplasmic pools and not from low-affinity extracellular receptors. Conversely, strain in the presence of heparin released 25.2 +/- 3.5% of the total FGF-2 (versus 15.6 +/- 2.6% for strain alone, P < .05). Thus, cellular strain closely modulates the release of intracellular FGF-2 from human vascular smooth muscle cells, but FGF-2 release is negligible in response to the smaller strains that occur in the normal artery. In addition, larger mechanical strains lead to transfer of intracellular FGF-2 to the extracellular low-affinity receptors, where FGF-2 may be displaced by heparin. These observations provide insight into the mechanisms by which deforming vascular injury, such as that produced by arterial interventions, may elicit a proliferative response.
尽管成纤维细胞生长因子2(FGF - 2)参与血管损伤反应,但细胞变形在FGF - 2释放中的作用尚未完全明确。为验证机械应变严格控制FGF - 2释放这一假说,采用一种新型装置对人血管平滑肌细胞施加均匀且一致的双轴应变。FGF - 2的释放量随应变循环次数增加(14%,1Hz);分别施加1次、9次和90次应变循环后,释放的FGF - 2分别占细胞内FGF - 2总量的0.55±0.06%、2.9±0.3%和5.5±1.3%(而对照组为0.00±0.40%,P <.05),但90至90000次应变循环时释放量未进一步增加。FGF - 2的机械释放取决于变形的频率和幅度。例如,4%幅度的应变(90次循环,1Hz)仅释放了FGF - 2总量的0.1±0.1%,但14%和33%幅度的应变分别释放了细胞内FGF - 2池的5.7±0.5%和19.0±3.0%(P <.05),提示FGF - 2释放存在应变幅度阈值。细胞亚群的损伤随应变频率和幅度增加,但幅度低于10%的应变不会导致细胞损伤。肝素预处理后施加应变释放了FGF - 2总量的12.6±1.6%(而单纯应变时为15.8±0.9%,P <.05),表明大部分FGF - 2是从核或细胞质池中释放出来的,而非来自低亲和力细胞外受体。相反,在肝素存在下施加应变释放了FGF - 2总量的25.2±3.5%(而单纯应变时为15.6±2.6%,P <.05)。因此,细胞应变紧密调节人血管平滑肌细胞内FGF - 2的释放,但正常动脉中出现的较小应变引起的FGF - 2释放可忽略不计。此外,较大的机械应变导致细胞内FGF - 2转移至细胞外低亲和力受体,在那里FGF - 2可能被肝素取代。这些观察结果为诸如动脉干预产生的血管变形损伤引发增殖反应的机制提供了深入见解。